13F Holdings
中文EN

COGT Cogent Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1622229 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-38.5%
TTM EPS YoY-10.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-99.6%
ROA-64.8%
ROIC (approx.)-89.9%
Asset turnover—

Leverage & solvency

Liabilities / assets38.0%
Debt / equity0.43x
Current ratio10.99x
Interest coverage-85.23x

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-13.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$269.78M$232.66M$173.75M$121.63M$55.91M
SG&A expense$63.58M$43.28M$34.38M$26.21M$19.64M
Operating income-$333.36M-$275.94M-$208.13M-$147.84M-$75.55M
Interest expense$3.06M————
Income tax$0————
Net income-$328.94M-$255.86M-$192.41M-$140.24M-$72.27M
EBITDA-$330.76M-$273.44M-$205.83M-$147.04M-$75.40M
EPS (basic)-2.16-1.94-1.94-1.73-1.87
EPS (diluted)-2.16-1.94-1.94-1.73-1.87
Weighted avg. shares (diluted)128.90M103.86M79.66M58.74M38.73M
Balance sheet
Cash & equivalents$312.01M$98.17M$53.23M$141.14M$220.94M
Short-term investments$588.75M$188.91M$212.48M$119.39M$0
Current assets$910.36M$296.47M$270.77M$264.97M$222.63M
PP&E, net$5.46M$6.47M$8.34M$7.78M$1.71M
Total assets$937.61M$327.90M$313.44M$300.81M$232.09M
Current liabilities$63.95M$55.71M$38.17M$26.85M$17.08M
Long-term debt$222.90M$0———
Total debt$222.90M$0———
Total liabilities$301.24M$71.61M$55.63M$45.08M$17.91M
Shareholders' equity$636.37M$256.29M$257.80M$255.74M$214.18M
Net debt-$89.12M-$98.17M———
Shares outstanding160.98M110.46M86.12M69.89M43.81M
Cash flow statement
Operating cash flow-$264.44M-$207.79M-$153.62M-$118.64M-$58.76M
Capital expenditure$1.55M$573,000$2.80M$6.86M$1.72M
Free cash flow-$266.00M-$208.36M-$156.42M-$125.50M-$60.48M
Investing cash flow-$399.53M$38.28M-$97.82M-$124.72M-$1.72M
Financing cash flow$878.23M$214.45M$163.54M$163.56M$37.98M
Depreciation & amortization$2.60M$2.50M$2.30M$800,000$147,000
Stock-based compensation$46.08M$39.74M$30.62M$18.37M$11.69M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.